{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:01:05Z","timestamp":1790190065594,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["222075\/Z\/20\/Z"],"award-info":[{"award-number":["222075\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["227288\/Z\/23\/Z"],"award-info":[{"award-number":["227288\/Z\/23\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR304266"],"award-info":[{"award-number":["NIHR304266"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s10928-026-10065-4","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:17:29Z","timestamp":1790187449000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Modelling the tail-phase pharmacokinetics of long-acting cabotegravir and rilpivirine from early pregnancy to postpartum at steady state"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1393-3753","authenticated-orcid":false,"given":"Shakir","family":"Atoyebi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0134-5855","authenticated-orcid":false,"given":"Catriona","family":"Waitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6588-5749","authenticated-orcid":false,"given":"Adeniyi","family":"Olagunju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"10065_CR1","unstructured":"UNAIDS (2025) Global HIV & AIDS statistics \u2014 Fact sheet 2024"},{"issue":"5","key":"10065_CR2","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3018(23)00028-0","volume":"10","author":"A Trickey","year":"2023","unstructured":"Trickey A, Sabin CA, Burkholder G, Crane H, d\u2019Arminio Monforte A, Egger M, Gill MJ, Grabar S, Guest JL, Jarrin I, Lampe FC, Obel N, Reyes JM, Stephan C, Sterling TR, Teira R, Touloumi G, Wasmuth J-C, Wit F, Wittkop L, Zangerle R, Silverberg MJ, Justice A, Sterne JAC (2023) Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. Lancet HIV 10(5):e295\u2013e307. https:\/\/doi.org\/10.1016\/S2352-3018(23)00028-0","journal-title":"Lancet HIV"},{"key":"10065_CR3","doi-asserted-by":"crossref","unstructured":"Gudala GR, Padayachee N, Vagiri RV (2025) Beyond antiretroviral treatment: Health-related quality of life of patients receiving antiretroviral treatment at a tertiary hospital in South Africa. Dialogues in Health 6:100207. https:\/\/doi.org\/10.1016\/j.dialog.2025.100207","DOI":"10.1016\/j.dialog.2025.100207"},{"issue":"Supplement_2","key":"10065_CR4","doi-asserted-by":"publisher","first-page":"S171","DOI":"10.1086\/313849","volume":"30","author":"MA Chesney","year":"2000","unstructured":"Chesney MA (2000) Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 30(Supplement_2):S171\u2013S176. https:\/\/doi.org\/10.1086\/313849","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10065_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-022-04896-5","volume":"22","author":"Y Alhassan","year":"2022","unstructured":"Alhassan Y, Twimukye A, Malaba T, Myer L, Waitt C, Lamorde M, Colbers A, Reynolds H, Khoo S, Taegtmeyer M (2022) \u201cI fear my partner will abandon me\u201d: the intersection of late initiation of antenatal care in pregnancy and poor ART adherence among women living with HIV in South Africa and Uganda. BMC Pregnancy Childbirth 22(1):566. https:\/\/doi.org\/10.1186\/s12884-022-04896-5","journal-title":"BMC Pregnancy Childbirth"},{"issue":"7","key":"10065_CR6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/qad.0000000000000613","volume":"29","author":"M Martin","year":"2015","unstructured":"Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Curlin ME, Na-pompet S, Warapronmongkholkul A, Kittimunkong S, Gvetadze RJ, McNicholl JM, Paxton LA, Choopanya K, Group ftBTS (2015) The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs. AIDS 29(7):819\u2013824. https:\/\/doi.org\/10.1097\/qad.0000000000000613","journal-title":"AIDS"},{"key":"10065_CR7","doi-asserted-by":"publisher","DOI":"10.1177\/23259582211009011","volume":"20","author":"KK Scarsi","year":"2021","unstructured":"Scarsi KK, Swindells S (2021) The promise of improved adherence with long-acting antiretroviral therapy: what are the data? Journal of the International Association of Providers of AIDS Care (JIAPAC) 20:23259582211009011. https:\/\/doi.org\/10.1177\/23259582211009011","journal-title":"Journal of the International Association of Providers of AIDS Care (JIAPAC)"},{"key":"10065_CR8","doi-asserted-by":"publisher","unstructured":"Landovitz RJ, Li S, Eron JJ Jr., Grinsztejn B, Dawood H, Liu AY, Magnus M, Hosseinipour MC, Panchia R, Cottle L, Chau G, Richardson P, Marzinke MA, Eshleman SH, Kofron R, Adeyeye A, Burns D, Rinehart AR, Margolis D, Cohen MS, McCauley M, Hendrix CW (2020) Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV 7(7):e472\u2013e481. https:\/\/doi.org\/10.1016\/S2352-3018(20)30106-5","DOI":"10.1016\/S2352-3018(20)30106-5"},{"issue":"4","key":"10065_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/bcp.16006","volume":"91","author":"S Atoyebi","year":"2025","unstructured":"Atoyebi S, Bunglawala F, Cottura N, Gra\u00f1ana-Castillo S, Montanha MC, Olagunju A, Siccardi M, Waitt C (2025) Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy. Br J Clin Pharmacol 91(4):989\u20131002. https:\/\/doi.org\/10.1111\/bcp.16006","journal-title":"Br J Clin Pharmacol"},{"key":"10065_CR10","doi-asserted-by":"crossref","unstructured":"Thoueille P, Choong E, Cavassini M, Buclin T, Decosterd LA (2022) Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. J Antimicrob Chemother 77(2):290\u2013302. https:\/\/doi.org\/10.1093\/jac\/dkab324","DOI":"10.1093\/jac\/dkab324"},{"issue":"8","key":"10065_CR11","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/00002030-199808000-00004","volume":"12","author":"M-L Newell","year":"1998","unstructured":"Newell M-L (1998) Mechanisms and timing of mother-to-child transmission of HIV-1. AIDS 12(8):831\u2013837","journal-title":"AIDS"},{"key":"10065_CR12","doi-asserted-by":"crossref","unstructured":"McGowan JP, Shah SS (2000) Prevention of perinatal HIV transmission during pregnancy. J Antimicrob Chemother 46(5):657\u2013668. https:\/\/doi.org\/10.1093\/jac\/46.5.657","DOI":"10.1093\/jac\/46.5.657"},{"issue":"4","key":"10065_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/v15040849","volume":"15","author":"MC Cardenas","year":"2023","unstructured":"Cardenas MC, Farnan S, Hamel BL, Mejia Plazas MC, Sintim-Aboagye E, Littlefield DR, Behl S, Punia S, Enninga EAL, Johnson E, Temesgen Z, Theiler R, Gray CM, Chakraborty R (2023) Prevention of the vertical transmission of HIV; a recap of the journey so far. Viruses 15(4):849","journal-title":"Viruses"},{"issue":"18","key":"10065_CR14","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1511691","volume":"375","author":"MG Fowler","year":"2016","unstructured":"Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, McIntyre J, Gnanashanmugam D, Siberry GK, Coletti AS (2016) Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med 375(18):1726\u20131737","journal-title":"N Engl J Med"},{"key":"10065_CR15","doi-asserted-by":"crossref","unstructured":"Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H (2012) Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinetics 51(6):365\u2013396. https:\/\/doi.org\/10.2165\/11597440-000000000-00000","DOI":"10.2165\/11597440-000000000-00000"},{"issue":"10","key":"10065_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15102455","volume":"15","author":"P Coppola","year":"2023","unstructured":"Coppola P, Butler A, Cole S, Kerwash E (2023) Total and free blood and plasma concentration changes in pregnancy for medicines highly bound to plasma proteins: application of physiologically based pharmacokinetic modelling to understand the impact on efficacy. Pharmaceutics 15(10):2455","journal-title":"Pharmaceutics"},{"key":"10065_CR17","doi-asserted-by":"crossref","unstructured":"Abduljalil K, Pansari A, Jamei M (2020) Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy. J Pharmacokinet Pharmacodyn 47(4):361\u2013383. https:\/\/doi.org\/10.1007\/s10928-020-09711-2","DOI":"10.1007\/s10928-020-09711-2"},{"key":"10065_CR18","doi-asserted-by":"crossref","unstructured":"Liu XI, Momper JD, Rakhmanina NY, Green DJ, Burckart GJ, Cressey TR, Mirochnick M, Best BM, van den Anker JN, Dallmann A (2020) Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling. Clin pharmacokinetics 59(11):1433\u20131450.https:\/\/doi.org\/10.1007\/s40262-020-00897-9","DOI":"10.1007\/s40262-020-00897-9"},{"issue":"4","key":"10065_CR19","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/bcp.16006","volume":"91","author":"S Atoyebi","year":"2025","unstructured":"Atoyebi S, Bunglawala F, Cottura N, Gra\u00f1ana-Castillo S, Montanha MC, Olagunju A, Siccardi M, Waitt C (2025) Physiologically\u2010based pharmacokinetic modelling of long\u2010acting injectable cabotegravir and rilpivirine in pregnancy. Br J Clin Pharmacol 91(4):989\u20131002","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"10065_CR20","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s40262-014-0185-7","volume":"53","author":"SA McCormack","year":"2014","unstructured":"McCormack SA, Best BM (2014) Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals. Clin Pharmacokinet 53(11):989\u20131004. https:\/\/doi.org\/10.1007\/s40262-014-0185-7","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"10065_CR21","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1097\/qad.0000000000003236","volume":"36","author":"H Coleman","year":"2022","unstructured":"Coleman H, Fox J, Chilton D (2022) The risks associated with stopping injectable antiretroviral treatment in women who are trying to conceive: a case series. AIDS 36(8):1205\u20131206. https:\/\/doi.org\/10.1097\/qad.0000000000003236","journal-title":"AIDS"},{"issue":"5","key":"10065_CR22","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/hiv.13439","volume":"24","author":"P Patel","year":"2023","unstructured":"Patel P, Ford SL, Baker M, Meyer C, Garside L, D\u2019Amico R, Van Solingen-Ristea R, Crauwels H, Polli JW, Seal C, Yag\u00fce Mu\u00f1oz I, Thiagarajah S, Birmingham E, Spreen WR, Baugh B, van Wyk J, Vannappagari V (2023) Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials. HIV Med 24(5):568\u2013579. https:\/\/doi.org\/10.1111\/hiv.13439","journal-title":"HIV Med"},{"key":"10065_CR23","doi-asserted-by":"crossref","unstructured":"Jones HM, Maurice D, Kuresh Y, R. GJ, J. AN, L. HT, K. GI, Raj LY, J. BP, C. JB, and Gardner IB (2012) Application of PBPK modelling in drug discovery and development at Pfizer. Xenobiotica 42 (1):94\u2013106. https:\/\/doi.org\/10.3109\/00498254.2011.627477","DOI":"10.3109\/00498254.2011.627477"},{"key":"10065_CR24","doi-asserted-by":"crossref","unstructured":"Montanha MC, Cottura N, Booth M, Hodge D, Bunglawala F, Kinvig H, Gra\u00f1ana-Castillo S, Lloyd A, Khoo S, Siccardi M (2022) PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease. Front Pharmacol 13:814134. https:\/\/doi.org\/10.3389\/fphar.2022.814134","DOI":"10.3389\/fphar.2022.814134"},{"issue":"3","key":"10065_CR25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40262-021-01067-1","volume":"61","author":"MC Montanha","year":"2022","unstructured":"Montanha MC, Fabrega F, Howarth A, Cottura N, Kinvig H, Bunglawala F, Lloyd A, Denti P, Waitt C, Siccardi M (2022) Predicting drug\u2013drug interactions between rifampicin and ritonavir-boosted atazanavir using PBPK modelling. Clin Pharmacokinet 61(3):375\u2013386. https:\/\/doi.org\/10.1007\/s40262-021-01067-1","journal-title":"Clin Pharmacokinet"},{"key":"10065_CR26","doi-asserted-by":"crossref","unstructured":"Cottura N, Kinvig H, Gra\u00f1ana-Castillo S, Wood A, Siccardi M (2022) Drug-Drug Interactions in People Living With HIV at Risk of Hepatic and Renal Impairment: Current Status and Future Perspectives. J Clin Pharmacol 62(7):835\u2013846. https:\/\/doi.org\/10.1002\/jcph.2025","DOI":"10.1002\/jcph.2025"},{"key":"10065_CR27","doi-asserted-by":"crossref","unstructured":"Atoyebi S, Montanha MC, Nakijoba R, Orrell C, Mugerwa H, Siccardi M, Denti P, Waitt C (2024) Physiologically based pharmacokinetic modeling of drug\u2013drug interactions between ritonavir-boosted atazanavir and rifampicin in pregnancy. CPT: Pharmacometrics & Systems Pharmacology n\/a (n\/a). https:\/\/doi.org\/10.1002\/psp4.13268","DOI":"10.21203\/rs.3.rs-5068722\/v1"},{"issue":"3","key":"10065_CR28","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/jac\/dkz506","volume":"75","author":"F Bunglawala","year":"2020","unstructured":"Bunglawala F, Rajoli RKR, Mirochnick M, Owen A, Siccardi M (2020) Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. J Antimicrob Chemother 75(3):640\u2013647. https:\/\/doi.org\/10.1093\/jac\/dkz506","journal-title":"J Antimicrob Chemother"},{"key":"10065_CR29","doi-asserted-by":"crossref","unstructured":"Bediako-Kakari P, Monyo M, Atoyebi S, Olagunju A (2025) Comparative modelling of foetal exposure to maternal long-acting injectable versus oral daily antipsychotics. npj Women\u2019s Health 3(1):31. https:\/\/doi.org\/10.1038\/s44294-025-00077-9","DOI":"10.1038\/s44294-025-00077-9"},{"issue":"5","key":"10065_CR30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/qai.0000000000000365","volume":"67","author":"W Spreen","year":"2014","unstructured":"Spreen W, Williams P, Margolis D, Ford SL, Crauwels H, Lou Y, Gould E, Stevens M, Piscitelli S (2014) Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J Acquir Immune Defic Syndr 67(5):487\u2013492. https:\/\/doi.org\/10.1097\/qai.0000000000000365","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10065_CR31","doi-asserted-by":"crossref","unstructured":"Ford SL, Sutton K, Lou Y, Zhang Z, Tenorio A, Trezza C, Patel P, Spreen W (2017) Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects. Antimicrob Agents Chemother 61(10). https:\/\/doi.org\/10.1128\/aac.00487-17","DOI":"10.1128\/AAC.00487-17"},{"key":"10065_CR32","unstructured":"Center for Drug Evaluation and Research (2011) Clinical Pharmacology and Biopharmaceutics Review(s). Addendum to Ondqa Biopharmaceutics review"},{"key":"10065_CR33","doi-asserted-by":"crossref","unstructured":"Crauwels H, Vingerhoets J, Ryan R, Witek J, Anderson D (2012) Pharmacokinetic Parameters of Once-Daily Rilpivirine following Administration of Efavirenz in Healthy Subjects. Antiviral Ther 17(3):439\u2013446. https:\/\/doi.org\/10.3851\/imp1959","DOI":"10.3851\/IMP1959"},{"issue":"11","key":"10065_CR34","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1093\/infdis\/jiy726","volume":"219","author":"RKR Rajoli","year":"2019","unstructured":"Rajoli RKR, Curley P, Chiong J, Back D, Flexner C, Owen A, Siccardi M (2019) Predicting drug-drug interactions between rifampicin and long-acting cabotegravir and rilpivirine using physiologically based pharmacokinetic modeling. J Infect Dis 219(11):1735\u20131742. https:\/\/doi.org\/10.1093\/infdis\/jiy726","journal-title":"J Infect Dis"},{"key":"10065_CR35","doi-asserted-by":"crossref","unstructured":"Watts DH, Stek A, Best BM, Wang J, Capparelli EV, Cressey TR, Aweeka F, Lizak P, Kreitchmann R, Burchett SK, Shapiro DE, Hawkins E, Smith E, Mirochnick M (2014) Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr 67(4):375\u2013381. https:\/\/doi.org\/10.1097\/qai.0000000000000318","DOI":"10.1097\/QAI.0000000000000318"},{"key":"10065_CR36","doi-asserted-by":"crossref","unstructured":"Osiyemi O, Yasin S, Zorrilla C, Bicer C, Hillewaert V, Brown K, Crauwels HM (2018) Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study. Infect Dis Ther 7(1):147\u2013159. https:\/\/doi.org\/10.1007\/s40121-017-0184-8","DOI":"10.1007\/s40121-017-0184-8"},{"key":"10065_CR37","doi-asserted-by":"crossref","unstructured":"Schalkwijk S, Colbers A, Konopnicki D, Gingelmaier A, Lambert J, van der Ende M, Molt\u00f3 J, Burger D, Network ftPondaaiH-ipw (2017) Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1\u2013Infected Women. Clin Infect Dis 65(8):1335\u20131341. https:\/\/doi.org\/10.1093\/cid\/cix534","DOI":"10.1093\/cid\/cix534"},{"key":"10065_CR38","doi-asserted-by":"crossref","unstructured":"Ford SL, Gould E, Chen S, Margolis D, Spreen W, Crauwels H, Piscitelli S (2013) Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Antimicrob Agents chemother 57(11):5472\u20135477. https:\/\/doi.org\/10.1128\/AAC.01235-13","DOI":"10.1128\/AAC.01235-13"},{"issue":"2","key":"10065_CR39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/s0379-0738(00)00401-1","volume":"119","author":"GL de la Grandmaison","year":"2001","unstructured":"de la Grandmaison GL, Clairand I, Durigon M (2001) Organ weight in 684 adult autopsies: new tables for a Caucasoid population. Forensic Sci Int 119(2):149\u2013154. https:\/\/doi.org\/10.1016\/s0379-0738(00)00401-1","journal-title":"Forensic Sci Int"},{"key":"10065_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.105068","volume":"140","author":"SA Atoyebi","year":"2019","unstructured":"Atoyebi SA, Rajoli RK, Adejuyigbe E, Owen A, Bolaji O, Siccardi M, Olagunju A (2019) Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: thalidomide versus efavirenz as case studies. Eur J Pharm Sci 140:105068","journal-title":"Eur J Pharm Sci"},{"key":"10065_CR41","unstructured":"ViiV Healthcare (2022) CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension). US Prescribing Information"},{"key":"10065_CR42","unstructured":"European Medicines Agency (2023) Apretude (cabotegravir). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/apretude. Accessed 13\/12\/2023 2023"},{"key":"10065_CR43","doi-asserted-by":"crossref","unstructured":"Rajoli RKR, Back DJ, Rannard S, Freel Meyers CL, Flexner C, Owen A, Siccardi M (2015) Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV. Clinical Pharmacokinetics 54(6):639\u2013650. https:\/\/doi.org\/10.1007\/s40262-014-0227-1","DOI":"10.1007\/s40262-014-0227-1"},{"key":"10065_CR44","doi-asserted-by":"crossref","unstructured":"Spreen W, Ford SL, Chen S, Wilfret D, Margolis D, Gould E, Piscitelli S (2014) GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. J Acquir Immune Defic Syndr 67(5):481\u2013486. https:\/\/doi.org\/10.1097\/qai.0000000000000301","DOI":"10.1097\/QAI.0000000000000301"},{"issue":"6","key":"10065_CR45","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01475-23","volume":"68","author":"K Han","year":"2024","unstructured":"Han K, Patel P, McCallister S, Rinehart AR, Gandhi Y, Spreen W, Landovitz RJ, Delany-Moretlwe S, Marzinke MA, McKeon T, Budnik P, Wyk J, Ford SL (2024) Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP. Antimicrob Agents Chemother 68(6):e01475-01423. https:\/\/doi.org\/10.1128\/aac.01475-23","journal-title":"Antimicrob Agents Chemother"},{"key":"10065_CR46","doi-asserted-by":"crossref","unstructured":"Thoueille P, Cavassini M, Guidi M, Buclin T, Girardin FR, Decosterd LA, Marzolini C (2024) Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures. Open Forum Infect Dis 11 (2):ofae023. https:\/\/doi.org\/10.1093\/ofid\/ofae023","DOI":"10.1093\/ofid\/ofae023"},{"issue":"12","key":"10065_CR47","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1093\/jac\/dkab338","volume":"76","author":"M Neyens","year":"2021","unstructured":"Neyens M, Crauwels HM, Perez-Ruixo JJ, Rossenu S (2021) Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV. J Antimicrob Chemother 76(12):3255\u20133262. https:\/\/doi.org\/10.1093\/jac\/dkab338","journal-title":"J Antimicrob Chemother"},{"key":"10065_CR48","doi-asserted-by":"crossref","unstructured":"Jogiraju V, Pawar P, Yager J, Ling J, Shen G, Chiu A, Hughes E, Palaparthy R, Carter C, Singh R (2025) Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study. The Lancet 405 (10485):1147\u20131154. https:\/\/doi.org\/10.1016\/S0140-6736(25)00405-2","DOI":"10.1016\/S0140-6736(25)00405-2"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-026-10065-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-026-10065-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-026-10065-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:17:37Z","timestamp":1790187457000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-026-10065-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["10065"],"URL":"https:\/\/doi.org\/10.1007\/s10928-026-10065-4","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"55"}}